238 related articles for article (PubMed ID: 28042702)
21. Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis.
Cappelli F; Baldasseroni S; Bergesio F; Perlini S; Salinaro F; Padeletti L; Attanà P; Paoletti Perini A; Moggi Pignone A; Grifoni E; Fabbri A; Marchionni N; Gensini GF; Perfetto F
Clin Cardiol; 2015 Feb; 38(2):69-75. PubMed ID: 25645201
[TBL] [Abstract][Full Text] [Related]
22. [Specific pharmacological treatment guide for transthyretin amyloid cardiomyopathy, 2021].
Villanueva E; Carretero M; Aguirre MA; Negro A; Belziti CA; Posadas-Martínez ML; Nucifora EM; Baratta S; Costabel JP; Higa C; Rivas C; Fernández A; Quiroga A; Dumont CA; Volberg VI; Streitenberg GM; Perez de Arenaza D
Medicina (B Aires); 2022; 82(2):275-288. PubMed ID: 35417392
[TBL] [Abstract][Full Text] [Related]
23. Disease-Modifying Treatments for Transthyretin Amyloidosis.
Tushak ZJ; Cox SZ; Cei LF; Gwathmey KG; Shah KB
J Cardiovasc Pharmacol; 2021 Nov; 78(5):e641-e647. PubMed ID: 34321398
[TBL] [Abstract][Full Text] [Related]
24. Wild-type transthyretin significantly contributes to the formation of amyloid fibrils in familial amyloid polyneuropathy patients with amyloidogenic transthyretin Val30Met.
Tsuchiya-Suzuki A; Yazaki M; Kametani F; Sekijima Y; Ikeda S
Hum Pathol; 2011 Feb; 42(2):236-43. PubMed ID: 21056899
[TBL] [Abstract][Full Text] [Related]
25. Myopathic phenotype of familial amyloid polyneuropathy with a rare transthyretin variant: ATTR Ala45Asp.
Misumi Y; Doki T; Ueda M; Obayashi K; Tasaki M; Tamura A; Ando Y
Amyloid; 2014 Sep; 21(3):216-7. PubMed ID: 24953234
[No Abstract] [Full Text] [Related]
26. Late-onset and fast progressive neuropathy and cardiomyopathy in Val32Ala transthyretin gene mutation.
Cazzato D; Dalla Bella E; Saveri P; Taroni F; Marucci G; Lauria G
Neurol Sci; 2019 Jun; 40(6):1267-1269. PubMed ID: 30685801
[TBL] [Abstract][Full Text] [Related]
27. Transthyretin amyloidosis in patients with undifferentiated heart failure.
Chang IC; Scott CG; Dispenzieri A; AbouEzzeddine O; Lin G; Grogan M
Amyloid; 2019; 26(sup1):33-34. PubMed ID: 31343280
[No Abstract] [Full Text] [Related]
28. Acoramidis in Transthyretin Amyloid Cardiomyopathy. Reply.
Gillmore JD; Lystig T; Fox JC
N Engl J Med; 2024 Apr; 390(14):1346-1347. PubMed ID: 38598813
[No Abstract] [Full Text] [Related]
29. Hereditary amyloid neuropathy by transthyretin Val107 mutation in a patient of African origin.
Cassereau J; Lavigne C; Letournel F; Ghali A; Verny C; Dubas F; Devière F; Nicolas G
J Peripher Nerv Syst; 2008 Sep; 13(3):251-4. PubMed ID: 18844793
[No Abstract] [Full Text] [Related]
30. Early identification of transthyretin-related hereditary cardiac amyloidosis.
Arbustini E; Merlini G
JACC Cardiovasc Imaging; 2014 May; 7(5):511-4. PubMed ID: 24831211
[No Abstract] [Full Text] [Related]
31. Hereditary transthyretin amyloidosis associated with a transthyretin variant Thr59Arg.
Watanabe T; Obayashi K; Misumi Y; Tasaki M; Shinriki S; Ando T; Akagami T; Ueda M; Yamashita T; Hirotani S; Ando Y
Amyloid; 2017 Mar; 24(sup1):119. PubMed ID: 28434332
[No Abstract] [Full Text] [Related]
32. A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells.
Michalon A; Hagenbuch A; Huy C; Varela E; Combaluzier B; Damy T; Suhr OB; Saraiva MJ; Hock C; Nitsch RM; Jan Grimm
Nat Commun; 2021 May; 12(1):3142. PubMed ID: 34035264
[TBL] [Abstract][Full Text] [Related]
33. Electrochemical skin conductance in hereditary amyloidosis related to transthyretin V30M - a promising tool to assess treatment efficacy?
Castro J; Costa J; de Castro I; Conceição I
Amyloid; 2018 Dec; 25(4):267-268. PubMed ID: 30773060
[No Abstract] [Full Text] [Related]
34. Transthyretin Cardiac Amyloidosis Due to Homozygous Val122Ile Mutation in a Caucasian Man.
Marrero Negrín N; Medina Gil JM; García Cruz ML; Jiménez Cabrera F
Rev Esp Cardiol (Engl Ed); 2019 Dec; 72(12):1086-1088. PubMed ID: 31561982
[No Abstract] [Full Text] [Related]
35. Evolution of amyloid fibrils in hereditary transthyretin amyloidosis: an ultrastructural study.
Koike H; Nishi R; Ikeda S; Kawagashira Y; Iijima M; Katsuno M; Sobue G
Amyloid; 2019; 26(sup1):26. PubMed ID: 31343346
[No Abstract] [Full Text] [Related]
36. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H
Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059
[No Abstract] [Full Text] [Related]
37. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis.
Damy T; Judge DP; Kristen AV; Berthet K; Li H; Aarts J
J Cardiovasc Transl Res; 2015 Mar; 8(2):117-27. PubMed ID: 25743445
[TBL] [Abstract][Full Text] [Related]
38. In brief: Tafamidis (Vyndaqel; Vyndamax) for transthyretin amyloid cardiomyopathy.
Med Lett Drugs Ther; 2020 Jan; 62(1590):16. PubMed ID: 31999671
[No Abstract] [Full Text] [Related]
39. Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis.
Hendren NS; Roth LR; Grodin JL
Curr Heart Fail Rep; 2020 Jun; 17(3):77-83. PubMed ID: 32356182
[TBL] [Abstract][Full Text] [Related]
40. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.
Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T
J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
